You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In PLOS this week: immune-related gene pairs linked to malignant melanoma outcomes, plasticity among paramyxoviruses, and more.
In Cell this week: analysis of multisystem inflammatory syndrome in children with SARS-CoV-2, fecal transplants boost gut microbiome development in infants born by C-section, and more.
Methylation profiles of more than 23,000 individuals uncovered thousands of epivariations, including some affecting Mendelian disease genes.
The funding is being provided under the NYGC's Polyethnic-1000 initiative, which was launched in 2018 to study cancer care inequities in underserved populations.
A computational method, coupled with PCR analysis and RNA-seq, helped researchers pinpoint several drugs that could be repurposed to fight COVID-19.
Mount Sinai researchers investigated four cytokine proteins and found that two of them were elevated in the serum samples of SARS-CoV-2 patients who fared the worst.
The firms will initially use RenalytixAI's KidneyIntelX platform to help improve outcomes for patients with chronic kidney disease and its complications.
Sequencing and other analyses helped uncover a JAK1 variant within a patient with an unknown autoimmune disorder disease and find a treatment approach.
BlackRock, the world's largest investment manager, led the round, joined by new investors Deerfield Management and Moore Strategic Ventures as well as existing investors.
With a three-pronged approach, a team led by Mount Sinai researchers examined the functional effects of noncoding de novo mutations on cardiac development.
The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.
A new UK government says socioeconomic factors, not genetics, account for disparities in deaths due to COVID-19 between ethnic groups, the Financial Times reports.
NPR reports on an Alzheimer's disease drug trial that is continuing despite the pandemic.
In Nature this week: CRISPR-Cas3 system for making large deletions efficiently, more.